1 |
QIN S, XIAO W, ZHOU C, et al.. Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics[J/OL]. Signal. Transduct. Target. Ther., 2022, 7(1): 199[2023-12-02]. .
|
2 |
曾桃花,李文茹,谢小保,等.植物精油对铜绿假单胞菌群体感应系统的抑制作用研究进展[J].生物技术进展,2021,11(3):279-288.
|
|
ZENG T H, LI W R, XIE X B, et al.. Research progress in the inhibitory effects of essential oils on the quorum sensing system of Pseudomonas aeruginosa [J]. Curr. Biotechnol., 2021, 11(3): 279-288.
|
3 |
CURRAN C S, BOLIG T, TORABI-PARIZI P. Mechanisms and targeted therapies for Pseudomonas aeruginosa lung infection[J]. Am. J. Respir. Crit. Care Med., 2018, 197(6): 708-727.
|
4 |
MIDDLETON M A, LAYEGHIFARD M, KLINGEL M, et al.. Epidemiology of clonal Pseudomonas aeruginosa infection in a Canadian cystic fibrosis population[J]. Ann. Am. Thorac. Soc., 2018, 15(7): 827-836.
|
5 |
OCHMAN H, MORAN N A. Genes lost and genes found: evolution of bacterial pathogenesis and symbiosis[J]. Science, 2001, 292(5519): 1096-1099.
|
6 |
ANTUNES M B, COHEN N A. Mucociliary clearance: a critical upper airway host defense mechanism and methods of assessment[J]. Curr. Opin. Allergy Clin. Immunol., 2007, 7(1): 5-10.
|
7 |
O'CONNELL K M, HODGKINSON J T, SORE H F, et al.. Combating multidrug-resistant bacteria: current strategies for the discovery of novel antibacterials[J]. Angew. Chem. Int. Ed., 2013, 52(41): 10706-10733.
|
8 |
MCGEACHY M J, CUA D J, GAFFEN S L. The IL-17 family of cytokines in health and disease[J]. Immunity, 2019, 50(4): 892-906.
|
9 |
PAPPU R, RUTZ S, OUYANG W. Regulation of epithelial immunity by IL-17 family cytokines[J]. Trends Immunol., 2012, 33(7): 343-349.
|
10 |
IWAKURA Y, ISHIGAME H, SAIJO S, et al.. Functional specialization of interleukin-17 family members[J]. Immunity, 2011, 34(2): 149-162.
|
11 |
ASADA Y, SUZUKI I, SUZUKI M, et al.. Atypical multiple benign osteoblastomas accompanied by simple bone cysts: a case report[J]. J. Cranio Maxill. Surg., 1991, 19(4): 166-171.
|
12 |
JEON Y J, JO A, WON J, et al.. IL-17C protects nasal epithelium from Pseudomonas aeruginosa infection[J]. Am. J. Respir. Cell Mol. Biol., 2020, 62(1): 95-103.
|
13 |
PAPAZIAN L, KLOMPAS M, LUYT C E. Ventilator-associated pneumonia in adults: a narrative review[J]. Intensive Care Med., 2020, 46(5): 888-906.
|
14 |
PALAVUTITOTAI N, JITMUANG A, TONGSAI S, et al.. Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections[J/OL]. PLoS ONE, 2018, 13(2): e0193431[2018-02-23]. .
|
15 |
RICHARDS M J, EDWARDS J R, CULVER D H, et al.. Nosocomial infections in combined medical-surgical intensive care units in the United States[J]. Infect. Contr. Hosp. Epidemiol., 2000, 21(8): 510-515.
|
16 |
LISTER P D, WOLTER D J, HANSON N D. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms[J]. Clin. Microbiol. Rev., 2009, 22(4): 582-610.
|
17 |
GILADI M, PORAT Y, BLATT A, et al.. Microbial growth inhibition by alternating electric fields in mice with Pseudomonas aeruginosa lung infection[J]. Antimicrob. Agents Chemother., 2010, 54(8): 3212-3218.
|
18 |
NOORANIDOOST M, COGAN N G, STOODLEY P, et al.. Bayesian estimation of Pseudomonas aeruginosa viscoelastic properties based on creep responses of wild type, rugose, and mucoid variant biofilms[J/OL]. Biofilm, 2023, 5:100133[2023-07-03]. .
|
19 |
GAGNE-THIVIERGE C, BARBEAU J, LEVESQUE R C, et al.. A new approach to study attached biofilms and floating communities from Pseudomonas aeruginosa strains of various origins reveals diverse effects of divalent ions[J/OL]. FEMS Microbiol. Lett., 2018, 365: 14[2018-06-27]. .
|
20 |
DAVIES J, DAVIES D. Origins and evolution of antibiotic resistance[J]. Microbiol. Mol. Biol. Rev., 2010, 74(3): 417-433.
|
21 |
LE ROUZIC O, PICHAVANT M, FREALLE E, et al.. Th17 cytokines: novel potential therapeutic targets for COPD pathogenesis and exacerbations[J]. Eur. Respir. J., 2017, 50: 4[2023-12-02]. .
|
22 |
CHEN K, POCIASK D A, MCALEER J P, et al.. IL-17RA is required for CCL2 expression, macrophage recruitment, and emphysema in response to cigarette smoke[J/OL]. PLoS ONE, 2011, 6(5): e20333[2023-01-02]. .
|
23 |
XU X, SHAO B, WANG R, et al.. Role of interleukin-17 in defense against pseudomonas aeruginosa infection in lungs[J]. Int. J. Clin. Exp. Med., 2014, 7(4): 809-816.
|
24 |
CONTI H R, GAFFEN S L. IL-17-mediated immunity to the opportunistic fungal pathogen Candida albicans [J]. J. Immunol. 2015, 195(3): 780-788.
|
25 |
HAPPEL K I, ZHENG M, YOUNG E, et al.. Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection[J]. J. Immunol., 2003, 170(9): 4432-4436.
|
26 |
MA W T, YAO X T, PENG Q, et al.. The protective and pathogenic roles of IL-17 in viral infections: friend or foe?[J/OL] Open Biol., 2019, 9(7): 190109[2019-07-25]. .
|
27 |
BAYES H K, RITCHIE N D, EVANS T J. Interleukin-17 is required for control of chronic lung infection caused by Pseudomonas aeruginosa [J]. Infect. Immun., 2016, 84(12): 3507-3516.
|
28 |
MEYER N J, GATTINONI L, CALFEE C S. Acute respiratory distress syndrome[J]. Lancet Lond. Engl., 2021, 398(10300): 622-637.
|
29 |
ME R, GAO N, DAI C, et al.. IL-17 promotes Pseudomonas aeruginosa keratitis in C57BL/6 mouse corneas[J]. J. Immunol., 2020, 204(1): 169-179.
|